Abstract
The global outbreak of human monkeypox (mpox) in 2022, declared a Public Health Emergency of International Concern by the WHO, has underscored the urgent need for effective diagnostic tools. In August 2024 WHO again declared mpox as a Public Health Emergency of International Concern. This study presents an innovative approach using artificial intelligence (AI) to design primers for the rapid and accurate detection of mpox. Leveraging evolutionary algorithms, we developed primer sets with high specificity and sensitivity, validated in silico for mpox main lineage and the Clade 1b. These primers are crucial for distinguishing mpox from other viruses, enabling precise diagnosis and timely public health responses. Our findings highlight the potential of AI-driven methodologies to enhance surveillance, vaccination strategies, and outbreak management, particularly for emerging zoonotic diseases. The emergence of new mpox clades, such as Clade 1b, with higher mortality rates, further emphasizes the necessity for continuous monitoring and preparedness for future pandemics. This study advocates for the integration of AI in molecular diagnostics to improve public health outcomes.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵* a.lopezrincon{at}uu.nl
Data Availability
The exact data belongs to GISAID, we shared just the results from the analysis in the Github. The IDs of the viral samples are available in the Github.
